THE YEAR IN BRIEF
AddLife 2023
During the year, AddLife has steadily adapted to support healthcare systems in the return to a normalised situation after COVID-19, while also helping to manage the healthcare queues that grew significantly during the pandemic.
Sales in all business areas showed a favourable trend and organic growth, excluding COVID-19 related sales and exchange rate fluctuations, reached a robust 10%.
|
9 685 |
1 135 |
773 |
As expected, COVID-19-related sales gradually ceased and were replaced in 2022 by acquired growth, mainly in the Medtech business area, followed by strong organic growth in both business areas in 2023.
|
Dynamisk graf: AddLife net sales by market 2023
|
Dynamisk graf: Earnings growth
|
Improving profitability and cash flow was a priority during the year. Following a thorough analysis of eye surgery and digital solutions in Homecare, strategic measures were adopted at year-end which will generate substantial positive effects on growth, profitability, and cash flow in 2024 and beyond. The positive market trend and robust cash flow in the latter part of the year align with our aim to reduce net debt through internally generated cash flow and, over time, increase the pace of acquisitions.
